In 2021, 529 million people were living with diabetes worldwide, and an estimated 1·31 billion individuals are projected to ...

The drug enhances outcomes in a high-risk patient population with a significant unmet need. Tirzepatide significantly ...

Researchers in Dallas want to know if the class of drugs, GIP/GLP-1 receptor agonists, might be a secret weapon in the fight ...

A new generation of oral weight loss medications could transform the fight against obesity and diabetes in low- and ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose ...

Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

There is a need to identify patients with obstructive sleep apnea after a weight-loss drug was approved for treatment of the ...

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

The future for GLP-1RA compounders, steps pharma can take in light of rising trial costs, funding ultra-rare therapies, and ...

With everything else going on in the world, it can be easy to miss new discoveries in biomedical science. Biomedical research ...

GLP-1s such as semaglutide and tirzepatide, originally formulated to treat patients with diabetes, have been touted as a solution for weight loss.